> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Comments on Drug Safety Surveillance Best Practices
- URL: https://www.fdaweb.com/comments-on-drug-safety-surveillance-best-practices/
- Published: 2020-03-09T12:00:00.000Z
- Updated: 2026-09-14T16:06:15.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5146275

*Federal Register* notice: FDA has reopened until 5/5 the comment period for a 11/7/2019 notice on a draft document entitled “Best Practices in Drug and Biological Product Postmarket Safety Surveillance for FDA Staff.” The document discusses risk-based principles that support ongoing FDA postmarketing safety surveillance for drug and biological products. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2020-03-06/pdf/2020-04591.pdf?ref=fdaweb.com).